The Latin America, Middle East and Africa Continuous Glucose Monitoring Device Market would witness market growth of 13.4% CAGR during the forecast period (2020-2026). The CGM displays a glucose trend graph and direction arrows that enable people with diabetes to predict rising glucose levels and lows, thus alerting the user at distracted periods such as playing, sleeping or exercising. The demand for CGM products is projected to gain significant momentum due to collaborations between endocrinologists, credentialed diabetes educators, and diabetes prevention stakeholder organizations.
Growing cases of diabetes have accelerated the market, along with the rising use of continuous glucose monitoring (CGM) devices. CGM devices are minimally invasive and provide a simple and reliable approach to diabetes treatment. They can also track dramatic changes in levels of blood glucose, thereby avoiding hypoglycemic disorders.
Through the assistance of a sensor, these instruments enable the analysis of blood glucose levels at different time intervals. Respective readings fed in via a wireless network to a diabetes treatment software allow patients to better understand the condition, thereby allowing them to treat it more effectively.The main risk factors associated with diabetes problems are smoking, obesity, physical inactivity, and high blood pressure and elevated cholesterol.
Based on Component, the market is segmented into Sensors, Transmitters, and Receivers. Based on End User, the market is segmented into Hospitals, Homecare Settings and Other End Users. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: Continuous Glucose Monitoring Device Market in LAMEA is expected to register a CAGR of 13.4% during the forecast period (2020-2026)
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, DexCom, Inc., Ypsomed AG, Senseonics Holdings, Inc., GlySens, Incorporated, A. Menarini Diagnostics Ltd. (The Menarini Group), Echo Therapeutics, Inc., Johnson and Johnson.
Market Segmentation:
By Component
By End User
By Country
Companies Profiled
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 